179 related articles for article (PubMed ID: 37331368)
1. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
Stambler BS; Camm AJ; Alings M; Dorian P; Heidbuchel H; Houtgraaf J; Kowey PR; Merino JL; Mondésert B; Piccini JP; Pokorney SD; Sager PT; Verma A; Wharton JM; Bharucha DB; Plat F; Shardonofsky S; Chen M; Ip JE;
Lancet; 2023 Jul; 402(10396):118-128. PubMed ID: 37331368
[TBL] [Abstract][Full Text] [Related]
2. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
Stambler BS; Plat F; Sager PT; Shardonofsky S; Wight D; Potvin D; Pandey AS; Ip JE; Coutu B; Mondésert B; Sterns LD; Bennett M; Anderson JL; Damle R; Haberman R; Camm AJ
Circ Arrhythm Electrophysiol; 2022 Dec; 15(12):e010915. PubMed ID: 36441560
[TBL] [Abstract][Full Text] [Related]
3. Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
Ip JE; Coutu B; Bennett MT; Pandey AS; Stambler BS; Sager P; Chen M; Shardonofsky S; Plat F; Camm AJ
J Am Heart Assoc; 2023 Oct; 12(19):e028227. PubMed ID: 37753718
[TBL] [Abstract][Full Text] [Related]
4. Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia.
Stambler BS; Plat F; Sager PT; Lubkov V; Shardonofsky S; Wight D; Chen M; Camm AJ
Am Heart J; 2022 Nov; 253():20-29. PubMed ID: 35728658
[TBL] [Abstract][Full Text] [Related]
5. Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trial.
Stambler BS; Ip JE
Cardiol Ther; 2023 Dec; 12(4):545-555. PubMed ID: 37950144
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
Ip JE; Bui H; Camm AJ; Coutu B; Noseworthy PA; Parody ML; Sears SF; Singh N; Uribe JA; Vyselaar J; Omodele S; Shardonofsky S; Bharucha DB; Stambler B
Am Heart J; 2024 Apr; 270():55-61. PubMed ID: 38266665
[TBL] [Abstract][Full Text] [Related]
7. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm.
Stambler BS; Dorian P; Sager PT; Wight D; Douville P; Potvin D; Shamszad P; Haberman RJ; Kuk RS; Lakkireddy DR; Teixeira JM; Bilchick KC; Damle RS; Bernstein RC; Lam WW; O'Neill G; Noseworthy PA; Venkatachalam KL; Coutu B; Mondésert B; Plat F
J Am Coll Cardiol; 2018 Jul; 72(5):489-497. PubMed ID: 30049309
[TBL] [Abstract][Full Text] [Related]
8. Plain language summary of the safety and effectiveness of etripamil for atrioventricular-nodal-dependent supraventricular tachycardia: the RAPID study.
Ip JE; Stambler BS; Bharucha DB; Green A
Future Cardiol; 2024 Feb; 20(2):35-44. PubMed ID: 38385329
[TBL] [Abstract][Full Text] [Related]
9. Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT).
Kashou AH; Noseworthy PA
Expert Opin Investig Drugs; 2020 Jan; 29(1):1-4. PubMed ID: 31825681
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast-Acting, Nondihydropyridine Calcium Channel Blocker.
Ip JE; Wight D; Yue CS; Nguyen D; Plat F; Stambler BS
Clin Pharmacol Drug Dev; 2024 Apr; 13(4):367-379. PubMed ID: 38315144
[TBL] [Abstract][Full Text] [Related]
11. Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia.
Calvert P; Gupta D
Future Cardiol; 2024; 20(3):163-170. PubMed ID: 38717391
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Camm AJ; Piccini JP; Alings M; Dorian P; Gosselin G; Guertin MC; Ip JE; Kowey PR; Mondésert B; Prins FJ; Roux JF; Stambler BS; van Eck J; Al Windy N; Thermil N; Shardonofsky S; Bharucha DB; Roy D
Circ Arrhythm Electrophysiol; 2023 Dec; 16(12):639-650. PubMed ID: 37950726
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abuelazm M; Kambalapalli S; Saleh O; Elzeftawy MA; Albakri K; Gowaily I; Abdelazeem B
Am J Cardiovasc Drugs; 2023 Jul; 23(4):379-391. PubMed ID: 37351813
[TBL] [Abstract][Full Text] [Related]
14. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
DiMarco JP; Miles W; Akhtar M; Milstein S; Sharma AD; Platia E; McGovern B; Scheinman MM; Govier WC
Ann Intern Med; 1990 Jul; 113(2):104-10. PubMed ID: 2193560
[TBL] [Abstract][Full Text] [Related]
15. Etripamil: Intranasal Calcium Channel Blocker: A Novel Noninvasive Modality in the Treatment of Paroxysmal Supraventricular Tachycardia.
Raja JM; Cave B; Jefferies JL; Khouzam RN
Curr Probl Cardiol; 2021 Mar; 46(3):100430. PubMed ID: 31279494
[No Abstract] [Full Text] [Related]
16. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia.
Huston J; Genovese A; Ashchi A; DeLuca A; Wiener J; Deeb E; Deeb A; Goldfaden RF
Am J Cardiovasc Drugs; 2023 Sep; 23(5):471-475. PubMed ID: 37278974
[TBL] [Abstract][Full Text] [Related]
17. Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia.
Chu GS; Gupta D
Heart Int; 2021; 15(1):2-6. PubMed ID: 36277324
[TBL] [Abstract][Full Text] [Related]
18. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group.
Dougherty AH; Jackman WM; Naccarelli GV; Friday KJ; Dias VC
Am J Cardiol; 1992 Sep; 70(6):587-92. PubMed ID: 1510006
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
Alboni P; Tomasi C; Menozzi C; Bottoni N; Paparella N; Fucà G; Brignole M; Cappato R
J Am Coll Cardiol; 2001 Feb; 37(2):548-53. PubMed ID: 11216977
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group.
Jordaens L; Gorgels A; Stroobandt R; Temmerman J
Am J Cardiol; 1991 Jul; 68(1):35-40. PubMed ID: 2058557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
